427 Plasma and urinary pharmacokinetics of the novel, oral SHIP1 activator, AQX-1125 in interstitial cystitis/bladder pain syndrome (IC/BPS): Results of the phase2 LEADERSHIP trial
Keyword(s):
2014 ◽
Vol 23
(6)
◽
pp. 751-757
◽
Keyword(s):
Keyword(s):
2019 ◽
Vol 26
(S1)
◽
pp. 20-24
◽
Keyword(s):